Market Forecast By Prescription Type (Prescription Drugs, Over-the-Counter Drugs), By Drug Type (Branded Drugs, Generic Drugs, Branded Generic Drugs), By Drug Class (Small Molecules, Biologics, Biosimilars), By Indication (Cardiovascular Diseases, Immunology, Respiratory Diseases, Neurological Diseases, Infectious Diseases, Skin Diseases), By Mode of Administration (Topical, Oral, Injectable, Intra-nasal, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies) And Competitive Landscape
| Product Code: ETC6058358 | Publication Date: Sep 2024 | Updated Date: Dec 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Deep | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
According to 6Wresearch internal database and industry insights, the Algeria Pharmaceutical Market is projected to grow at a compound annual growth rate (CAGR) of 5.9% during the forecast period (2026-2032).
Below mentioned are the evaluation of years-wise growth rate along with key growth drivers:
| Year | Est. Annual Growth (%) | Growth Drivers |
| 2021 | 3.1% | Expansion of public healthcare facilities and structured medicine procurement programs |
| 2022 | 3.8% | Increased focus on domestic pharmaceutical manufacturing initiatives |
| 2023 | 4.4% | Rising demand for long-term medications addressing chronic disease management |
| 2024 | 5% | Strengthened drug distribution networks alongside retail pharmacy expansion |
| 2025 | 5.5% | Growing government support for local generic drug production and supply stability |
The Algeria Pharmaceutical Market report thoroughly covers the market by Prescription Type, Drug Type, Drug Class, Indication, Mode of Administration and Distribution Channel. The market report provides an unbiased and detailed analysis of ongoing market trends, opportunities/high growth areas, and market drivers, which help stakeholders devise and align their market strategies according to the current and future market dynamics.
| Parameter | Details |
| Report Name | Algeria Pharmaceutical Market |
| Forecast Period | 2026–2032 |
| CAGR | 5.90% |
| Growing Sector | Generic Drugs |
The Algeria Pharmaceutical Market is anticipated to experience a steady growth phase, a trend that finds its support in the increment of healthcare expenditure, the rise in the prevalence of chronic illnesses, and a persistent government attention to strengthening the drug manufacturing capabilities in the domestic sector. Generally, demand for affordable medicines continues to rise due to population growth and improved access to healthcare services across urban and semi-urban regions. Moreover, regulatory support for local production and controlled imports is improving medicine availability while supporting long-term pharmaceutical market stability.
Below mentioned are some prominent drivers and their influence to the market dynamics:
| Drivers | Primary Segments Affected | Why it Matters (Evidence) |
| Expansion of Local Drug Manufacturing | Generic Drugs, Hospitals | Domestic production lowers import reliance and ensures a stable, continuous supply of essential medicines. |
| Rising Chronic Disease Burden | Cardiovascular, Diabetes Medicines | Long-term treatment requirements increase consistent demand for pharmaceutical products. |
| Government Price Control Policies | All Drug Types | Regulated pricing enhances medicine affordability and expands patient access across income groups. |
| Retail Pharmacy Network Growth | OTC Drugs, Retail Pharmacies | Wider pharmacy coverage improves medicine availability in urban and semi-urban regions. |
| Improved Healthcare Coverage | Hospitals, Prescription Drugs | More public healthcare expenditures bring about a rise in the consumption of prescription drugs. |
Algeria Pharmaceutical Market is expected to grow at the CAGR of 5.9% during the forecast period of 2026-2032. Growth is supported by increasing healthcare demand, rising domestic drug production, and structured government pricing regulations. Furthermore, improvements in pharmaceutical distribution infrastructure and higher awareness regarding preventive healthcare are strengthening consistent market expansion across therapeutic categories.
Below mentioned are some major restraints and their influence to the market dynamics:
| Restraints | Primary Segments Affected | What This Means (Evidence) |
| Regulatory Approval Delays | Branded Drugs, Biologics | Lengthy regulatory review processes slow down the introduction of new and advanced pharmaceutical products. |
| Dependence on Imported Raw Materials | All Drug Types | Changes in import availability and costs cause interruptions in the continuation of production as well as instability in pricing. |
| Pricing Pressure on Manufacturers | Generic Drugs, Local Firms | Price-controlled frameworks lead to a reduction of profit margins, thus limiting the possibilities of reinvestment in research and expansion of capacity. |
| Limited Cold Chain Infrastructure | Biologics, Injectable Drugs | Inadequate temperature-controlled storage restricts the wider distribution of sensitive formulations. |
| Fragmented Distribution Channels | Drug Stores, Online Pharmacies | Disconnected supply networks cause delays and inconsistencies in medicine availability. |
While the Algeria Pharmaceutical Industry has been gradually evolving, it is still facing a wide range of issues such as complex regulations, dependence on imported active ingredients, and a shortage of infrastructure for the production of biologics. Besides that, the imposition of price controls limits the profitability of firms, and the disparity in the distribution of medicines between urban and rural areas results in the inconsistent availability of drugs. It is still essential to tackle these structural problems by investing in infrastructure, facilitating regulations, and modernising the supply chain to achieve sustainable growth of the pharmaceutical market.
Major trends influencing the evolution of the Algeria Pharmaceutical Market include:
Key investment opportunities emerging throughout the Algerian Pharmaceutical Market include:
Some prominent companies actively participating in the Algeria Pharmaceutical Market include:
| Company Name | Sanofi S.A. |
| Established Year | 2004 |
| Headquarters | Paris, France |
| Official Website | Click Here |
Sanofi actively supplies cardiovascular and diabetes medicines while supporting local manufacturing partnerships in Algeria.
| Company Name | Novartis AG |
| Established Year | 1996 |
| Headquarters | Basel, Switzerland |
| Official Website | Click Here |
Novartis provides branded and generic medicines across oncology, neurology, and immunology segments.
| Company Name | Pfizer Inc. |
| Established Year | 1849 |
| Headquarters | New York, USA |
| Official Website | Click Here |
Pfizer supplies innovative and specialty medicines addressing chronic and infectious diseases.
| Company Name | Hikma Pharmaceuticals |
| Established Year | 1978 |
| Headquarters | London, United Kingdom |
| Official Website | Click Here |
Hikma focuses on affordable generics and injectables, strengthening medicine access in public hospitals.
| Company Name | SAIDAL Group |
| Established Year | 1982 |
| Headquarters | Algiers, Algeria |
| Official Website | Click Here |
SAIDAL is a key domestic manufacturer producing essential generic medicines for national healthcare programs.
According to Algerian Government Data, the Algeria Pharmaceutical Market is under regulation by well-organised healthcare policies, including the National Pharmaceutical Development Strategy that was put into effect in 2018 and focuses on local drug production and the availability of essential medicines as its main objectives. In addition to that, the Ministry of Health has put in place pricing control measures and has made the licensing process more rapid for domestic manufacturers. At the same time, by means of public-private partnerships, it is being promoted to be at a higher level, and the medicine is to be more accessible in the long run.
The Algeria Pharmaceutical Market is expected to maintain a positive trajectory going forward, as the market momentum is increasingly being consolidated by the three factors of ongoing government support, increasing local manufacturing capacity, and rising demand for chronic disease treatments. To a large extent, the opportunities for pharmaceutical value chains to be more operationally efficient and appealing for investors will come from advancements in biologics production, better regulatory transparency, and gradual uptake of digital health platforms.
The report offers a comprehensive study of the subsequent market segments and their leading categories.
According to Ashwini, Senior Research Analyst, 6Wresearch, Prescription Drugs continue to dominate the Algeria Pharmaceutical Market Share as the burden of chronic and lifestyle-related diseases steadily rises, requiring long-term and physician-supervised treatment regimens. Additionally, government-funded hospital procurement programs prioritise prescription medicines, leading to consistent demand, stable volumes, and sustained utilisation across cardiovascular, neurological, and infectious disease therapies.
Generic Drugs have been the major contributor in the Algeria Pharmaceutical Industry for quite some time, as the government has put a lot of focus on making medicines affordable, regulating prices, and achieving self-sufficiency in the supply of essential drugs. Local pharmaceutical manufacturers have been very active in the production of generic drugs as substitutes for brand-name products, making sure that these products are very accessible through public hospitals and retail pharmacies.
Small Molecules account for a major share of the pharmaceutical market in Algeria, and their market growth is largely due to their wide therapeutic application, well-optimised manufacturing processes, and lower production costs in comparison to biologics. These medications find extensive usage in the treatment of cardiovascular, respiratory, infectious, and neurological diseases which constitute the major disease burdens in the country. Additionally, strong local manufacturing capabilities and less demanding storage and distribution conditions also elevate their availability, making small molecules the most preferred ones in the hospital sector and among retail pharmacies.
The report offers a comprehensive study of the subsequent market segments:
| 1 Executive Summary |
| 2 Introduction |
| 2.1 Key Highlights of the Report |
| 2.2 Report Description |
| 2.3 Market Scope & Segmentation |
| 2.4 Research Methodology |
| 2.5 Assumptions |
| 3 Algeria Pharmaceutical Market Overview |
| 3.1 Algeria Country Macro Economic Indicators |
| 3.2 Algeria Pharmaceutical Market Revenues & Volume, 2022 & 2032F |
| 3.3 Algeria Pharmaceutical Market - Industry Life Cycle |
| 3.4 Algeria Pharmaceutical Market - Porter's Five Forces |
| 3.5 Algeria Pharmaceutical Market Revenues & Volume Share, By Prescription Type, 2022 & 2032F |
| 3.6 Algeria Pharmaceutical Market Revenues & Volume Share, By Drug Type, 2022 & 2032F |
| 3.7 Algeria Pharmaceutical Market Revenues & Volume Share, By Drug Class, 2022 & 2032F |
| 3.8 Algeria Pharmaceutical Market Revenues & Volume Share, By Indication, 2022 & 2032F |
| 3.9 Algeria Pharmaceutical Market Revenues & Volume Share, By Mode of Administration, 2022 & 2032F |
| 3.10 Algeria Pharmaceutical Market Revenues & Volume Share, By Distribution Channel, 2022 & 2032F |
| 4 Algeria Pharmaceutical Market Dynamics |
| 4.1 Impact Analysis |
| 4.2 Market Drivers |
| 4.2.1 Increasing prevalence of chronic diseases in Algeria |
| 4.2.2 Government initiatives to improve healthcare infrastructure |
| 4.2.3 Growing middle-class population with higher disposable income |
| 4.3 Market Restraints |
| 4.3.1 Stringent regulations and approval processes for pharmaceutical products |
| 4.3.2 Limited access to healthcare services in rural areas |
| 5 Algeria Pharmaceutical Market Trends |
| 6 Algeria Pharmaceutical Market, By Types |
| 6.1 Algeria Pharmaceutical Market, By Prescription Type |
| 6.1.1 Overview and Analysis |
| 6.1.2 Algeria Pharmaceutical Market Revenues & Volume, By Prescription Type, 2022 & 2032F |
| 6.1.3 Algeria Pharmaceutical Market Revenues & Volume, By Prescription Drugs, 2022 & 2032F |
| 6.1.4 Algeria Pharmaceutical Market Revenues & Volume, By Over-the-Counter Drugs, 2022 & 2032F |
| 6.2 Algeria Pharmaceutical Market, By Drug Type |
| 6.2.1 Overview and Analysis |
| 6.2.2 Algeria Pharmaceutical Market Revenues & Volume, By Branded Drugs, 2022 & 2032F |
| 6.2.3 Algeria Pharmaceutical Market Revenues & Volume, By Generic Drugs, 2022 & 2032F |
| 6.2.4 Algeria Pharmaceutical Market Revenues & Volume, By Branded Generic Drugs, 2022 & 2032F |
| 6.3 Algeria Pharmaceutical Market, By Drug Class |
| 6.3.1 Overview and Analysis |
| 6.3.2 Algeria Pharmaceutical Market Revenues & Volume, By Small Molecules, 2022 & 2032F |
| 6.3.3 Algeria Pharmaceutical Market Revenues & Volume, By Biologics, 2022 & 2032F |
| 6.3.4 Algeria Pharmaceutical Market Revenues & Volume, By Biosimilars, 2022 & 2032F |
| 6.4 Algeria Pharmaceutical Market, By Indication |
| 6.4.1 Overview and Analysis |
| 6.4.2 Algeria Pharmaceutical Market Revenues & Volume, By Cardiovascular Diseases, 2022 & 2032F |
| 6.4.3 Algeria Pharmaceutical Market Revenues & Volume, By Immunology, 2022 & 2032F |
| 6.4.4 Algeria Pharmaceutical Market Revenues & Volume, By Respiratory Diseases, 2022 & 2032F |
| 6.4.5 Algeria Pharmaceutical Market Revenues & Volume, By Neurological Diseases, 2022 & 2032F |
| 6.4.6 Algeria Pharmaceutical Market Revenues & Volume, By Infectious Diseases, 2022 & 2032F |
| 6.4.7 Algeria Pharmaceutical Market Revenues & Volume, By Skin Diseases, 2022 & 2032F |
| 6.5 Algeria Pharmaceutical Market, By Mode of Administration |
| 6.5.1 Overview and Analysis |
| 6.5.2 Algeria Pharmaceutical Market Revenues & Volume, By Topical, 2022 & 2032F |
| 6.5.3 Algeria Pharmaceutical Market Revenues & Volume, By Oral, 2022 & 2032F |
| 6.5.4 Algeria Pharmaceutical Market Revenues & Volume, By Injectable, 2022 & 2032F |
| 6.5.5 Algeria Pharmaceutical Market Revenues & Volume, By Intra-nasal, 2022 & 2032F |
| 6.5.6 Algeria Pharmaceutical Market Revenues & Volume, By Others, 2022 & 2032F |
| 6.6 Algeria Pharmaceutical Market, By Distribution Channel |
| 6.6.1 Overview and Analysis |
| 6.6.2 Algeria Pharmaceutical Market Revenues & Volume, By Hospital Pharmacies, 2022 & 2032F |
| 6.6.3 Algeria Pharmaceutical Market Revenues & Volume, By Retail Pharmacies, 2022 & 2032F |
| 6.6.4 Algeria Pharmaceutical Market Revenues & Volume, By Drug Stores, 2022 & 2032F |
| 6.6.5 Algeria Pharmaceutical Market Revenues & Volume, By Online Pharmacies, 2022 & 2032F |
| 7 Algeria Pharmaceutical Market Import-Export Trade Statistics |
| 7.1 Algeria Pharmaceutical Market Export to Major Countries |
| 7.2 Algeria Pharmaceutical Market Imports from Major Countries |
| 8 Algeria Pharmaceutical Market Key Performance Indicators |
| 8.1 Percentage increase in the number of pharmacies in urban areas |
| 8.2 Average waiting time for patients to receive prescribed medications |
| 8.3 Adoption rate of telemedicine services in Algeria |
| 9 Algeria Pharmaceutical Market - Opportunity Assessment |
| 9.1 Algeria Pharmaceutical Market Opportunity Assessment, By Prescription Type, 2022 & 2032F |
| 9.2 Algeria Pharmaceutical Market Opportunity Assessment, By Drug Type, 2022 & 2032F |
| 9.3 Algeria Pharmaceutical Market Opportunity Assessment, By Drug Class, 2022 & 2032F |
| 9.4 Algeria Pharmaceutical Market Opportunity Assessment, By Indication, 2022 & 2032F |
| 9.5 Algeria Pharmaceutical Market Opportunity Assessment, By Mode of Administration, 2022 & 2032F |
| 9.6 Algeria Pharmaceutical Market Opportunity Assessment, By Distribution Channel, 2022 & 2032F |
| 10 Algeria Pharmaceutical Market - Competitive Landscape |
| 10.1 Algeria Pharmaceutical Market Revenue Share, By Companies, 2025 |
| 10.2 Algeria Pharmaceutical Market Competitive Benchmarking, By Operating and Technical Parameters |
| 11 Company Profiles |
| 12 Recommendations |
| 13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here